Thermo Fisher's Clario Acquisition Deemed Earnings-Accretive by Bank of America

Deep News03-26

Bank of America stated that the biotechnology firm Thermo Fisher Scientific completed its acquisition of Clario Holdings on Tuesday, a deal that further solidifies its position as a beneficiary of artificial intelligence. Analyst Michael Rysin reaffirmed a "Buy" rating on Thermo Fisher Scientific and maintained a $700 price target, implying a 42% upside from Tuesday's closing price.

The all-cash transaction valued at $8.875 billion will see Thermo Fisher Scientific integrate Clario's AI-based data collection technologies to accelerate trial processes required for drug approvals. Rysin wrote that the acquisition positions Thermo Fisher Scientific as a platform structurally aligned with the realization of AI value.

Clario's digital endpoint infrastructure and meticulously curated real-world evidence datasets enhance Thermo Fisher Scientific's ability to capture AI-driven productivity gains, placing the company in a favorable position amid this transformation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment